CELL INTELLIGENCE · 肿瘤细胞治疗研究

用于治疗 GD2 阳性实体瘤的抗原诱导型 IL18 增强 CAR-T 细胞的临床前开发

Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.

这些结果为在神经母细胞瘤及其他 GD2 阳性肿瘤的儿童和成人患者中开展 GD2IL18CAR-T 的临床研究铺平了道路（EU CT 2022- 501725-21-00）。

尤因肉瘤的新兴疗法

Emerging therapies in Ewing sarcoma.

弥漫性中线胶质瘤的流行病学、诊断策略和治疗进展

Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma.

神经母细胞瘤患者 NK 细胞的代谢反应增强，提示免疫治疗潜力增加

Heightened metabolic responses in NK cells from patients with neuroblastoma suggests increased potential for immunotherapy.

儿童高级别胶质瘤的 CAR-T 治疗：特殊性、当前研究与未来策略

CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.